Estimation of Ribociclib and Letrozole in Solid Dosage form (Tablet): A Novel Analytical Method | Chapter 9 | Current Overview on Pharmaceutical Science Vol. 9

An attempt was created to develop a plain, rapid, and corroborated method for the concurrent estimation of ribociclib and letrozole together tablet portion of drug or other consumable form.Inhibitors of cyclin D1/CDK4 (Cyclin-dependent kinase 4) [2] and CDK6 (Cyclin-weak kinase 6) [2] are found in Ribociclib, which is retailed by Novartis under the brand names Kisqali and Kryxana. This drug is used to treat some types of feelings cancer. The mixture of aromatase inhibitors and fulvestrant Inhibitors of cyclin D1/CDK4 (Cyclin-dependent kinase 4) and CDK6 (Cyclin-reliant kinase 6) are found in Ribociclib, This drug is used to treat few types of breast malignancy. The combination of aromatase inhibitors and fulvestrant.The chromatographic break-up was carried out on Waters, proportion C18 (150 mm×4.6 mm with 3.5 µm), travelling phase secondhand was a mixture of safeguard and acetonitrile in the ratio of 80:20, accompanying flow rate of 1ml/min and dose volume of 10 µL for the assay. The detection was finished using PDA at 260 nm, accompanying run time of 5 brief time period. The retention opportunity for the drugs ribociclib and letrozole was detected expected 2.648 min and 3.151 brief time period, respectively. The pattern was validated in accordance with ICH guidelines.The extent of object of letrozole and ribociclib was observed expected in the range of 0.50–7.50 and 40.01–600.15, Correlation coefficient (r2) 0.999 and 0.9983, individually. Accuracy for ribociclib and letrozole is carried out by repeatable concentrations of 50%, 100%, and 150. Validation determinants of robustness and masculinity were detected to be in limits.The grown method was plain, rapid, and logical; it can be secondhand for the simultaneous belief of ribociclib and letrozole tablet portion of drug or other consumable form in routine analysis. The approved method maybe used for the routine reasoning of both the drugs from size and different formulations and will help in healing drug monitoring (TDM) and bioavailability studies.

Author(s) Details:

Bhagyalata Satapathy,
The Tamil Nadu Dr. M.G.R Medical University, India.

Chaitanya Bangari,
The Tamil Nadu Dr. M.G.R Medical University, India.

Please see the link here: https://stm.bookpi.org/COPS-V9/article/view/10178

Effects of Letrozole on Reproductive Organs of Male Rats of Different Ages | Chapter 5 | Issues and Developments in Medicine and Medical Research Vol.11

Aim: To investigate the reproductive organs in young male rats and those with age-related involution of reproductive organs after long-term administration of letrozole, a steroid aromatase inhibitor, followed by its withdrawal.

The experiments were carried out on Wistar rats aged 5 to 15 months, who were gavaged with letrozole at a dose of 1 mg/kg b. w every other day for 3 months and then ceased for 2 months. The levels of testosterone and estradiol in the blood plasma were determined using immunoassays. Spermatozoa concentrations in epididymal washes were measured. The gonads and ventral prostate morphology were studied, as well as the testicles and accessory sexual glands. The study's findings were compared to those of control animals of the same age.

As a result of letrozole treatment, the ratio of testosterone to estradiol in the blood plasma of aged rats rose. In the epididymis, the average number of spermatozoa increased by 28%. Leydig cells were functionally activated, according to histological examination, with significant delays in involutive changes in their number and form. Some of the Leydig cells had functional depletion symptoms. Letrozole raised the relative weights of the coagulation gland by 40%, seminal vesicles by 31%, and the ventral prostate by 33% as compared to control rats. Two months after the letrozole was stopped, there were no indicators of difference between the letrozole-treated and control animals. In young rats, the effects of letrozole were almost imperceptible.

Conclusions: Letrozole raises the testosterone/estradiol ratio in blood plasma, spermatozoa content in epididymia, and the weights of androgen-dependent accessory sexual glands in male rats with age-related involution of the reproductive system. After that, age-related morphological changes in the gonad and prostate gland slow down. Letrozole's effects on reproduction are reversible.

Author(s) Details:

A. G. Reznikov
V. P. Komisarenko Institute of Endocrinology and Metabolism, National Academy of Medical Sciences of Ukraine, 69 Vyshgorodska str., Kiev, 04114, Ukraine.


O. V. Sachynska,
V. P. Komisarenko Institute of Endocrinology and Metabolism, National Academy of Medical Sciences of Ukraine, 69 Vyshgorodska str., Kiev, 04114, Ukraine.


L. I. Polyakova,
V. P. Komisarenko Institute of Endocrinology and Metabolism, National Academy of Medical Sciences of Ukraine, 69 Vyshgorodska str., Kiev, 04114, Ukraine.

O. A. Faliush,
V. P. Komisarenko Institute of Endocrinology and Metabolism, National Academy of Medical Sciences of Ukraine, 69 Vyshgorodska str., Kiev, 04114, Ukraine.

A. V. Yanishevskiy,
V. P. Komisarenko Institute of Endocrinology and Metabolism, National Academy of Medical Sciences of Ukraine, 69 Vyshgorodska str., Kiev, 04114, Ukraine.

Please see the link here: https://stm.bookpi.org/IDMMR-V11/article/view/6077